Please assess the completion status of the following clinical trial:

Trial Title: Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* MDE as primary diagnosis according to DSM-IV-TR criteria (classification code 296.xx)~* Current MDE duration of at least 3 months and less than 12 months~* The patient has a MADRS total score \>=30~Exclusion Criteria:~* Any current psychiatric disorder other than MDD as defined in the DSM-IV TR~* Any substance disorder within the previous 6 months~* Female patients of childbearing potential who are not using effective contraception~* Use of any psychoactive medication 2 weeks prior to screening and during the study~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Vortioxetine (Lu AA21004) 5 mg (Type: EXPERIMENTAL): None
- Vortioxetine (Lu AA21004) 10 mg (Type: EXPERIMENTAL): None
- Venlafaxine XL 225 mg (Type: OTHER): Active Reference

Based on this trial design, predict the completion outcome and termination type (if applicable).